We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Die neue WHO-Klassifikation zur Einteilung der akuten myeloischen Leukämien (AML): Vorteile und Probleme im Vergleich zur FAB (French-American-British)-Klassifikation.
- Authors
Haferlach, T.; Schoch, C.; Hiddemann, W.
- Abstract
Since 25 years, the FAB classification has been used for acute myeloid leukemias (AML) and myelodysplastic syndromes (MDS). Now, the WHO has published a new classification that is primarily based on cytogenetic and molecular markers. Dysplastic features are also analyzed for further subcategories. In parallel, the history of the AML, whether "evolving from a MDS" or "therapy-related", is taken into account. The blast count for AML is newly defined to be more than 20 % (the threshold of 30 % was abolished). This WHO classification for AML points in the right direction by emphasizing the biology of the disease. Its value for diagnosis, therapy, prognosis and its clinial relevance for every single patient must be investigated prospectively.
- Publication
Journal of Laboratory Medicine / Laboratoriums Medizin, 2002, Vol 26, Issue 1/2, p19
- ISSN
0342-3026
- Publication type
Article